• About us
• Contact

Advertisement

Organisation › Details

Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT)

AMT, founded in 1998 and based in Amsterdam, is a leader in the development of human gene based therapies. Using AAV as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. This safe and efficacious proprietary platform offers a unique manufacturing capability which can be applied to a large number of rare (orphan) diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with several AAV-based gene therapy products in LPLD, Hemophilia B, DMD, Acute Intermittent Porphyria and Parkinson’s Disease at different stages of research or development. *

 

	Start	2007-06-20 renamed
	End	2012-04-05 dissolved
	Group	Uniqure (Group)
	Today	Uniqure N.V. (Nasdaq: QURE)
	Predecessor	Amsterdam Molecular Therapeutics B.V. (AMT)
	Industry	gene therapy
	Industry 2	adeno-associated viral vector (AAV vector)
	Region	Amsterdam
	Country	Netherlands
Basic data	Employees	B: 11 to 50 (2005-10-03)
	Currency	EUR
	Annual sales	223,000,000 (net income (2008, consolidated) 2008-12-31)
	Profit	-16,919,000 (2008-12-31)
	Cash	34,150,000 (2008-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Uniqure (Group)

• [1] Uniqure N.V.. (5/15/23). "Press Release: Uniqure Announces Sale of Royalty Interest in Hemgenix for up to $400 Million". Lexington, MA & Amsterdam....
• [2] Uniqure N.V.. (1/31/23). "Press Release: uniQure and Apic Bio Enter into Global Licensing Agreement for APB-102, a Clinical Stage Gene Therapy for Patients with ALS Caused by Mutations in SOD1". Lexington, MA, Amsterdam & Cambridge, MA....
• [3] Uniqure N.V.. (11/22/22). "Press Release: Uniqure Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B". Research Triangle Park, NC....
• [4] Uniqure N.V.. (12/9/21). "Press Release: Uniqure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B". Lexington, MA, Amsterdam & King of Prussia, PA....
• [5] Uniqure N.V.. (6/22/21). "Press Release: Uniqure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)". Lexington, MA, Amsterdam & Paris....
• [6] Uniqure N.V.. (12/21/20). "Press Release: uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program". Lexington, MA & Amsterdam....
• [7] Uniqure N.V.. (6/24/20). "Press Release: Uniqure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy". Lexington, MA & Amsterdam....
• [8] Uniqure N.V.. (6/17/20). "Press Release: Uniqure Announces the Appointment of Leonard E. Post, Ph.D. to Its Board of Directors". Lexington, MA & Amsterdam....
• [9] Uniqure N.V.. (3/2/20). "Press Release: Uniqure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters". Lexington, MA & Amsterdam....
• [10] Uniqure N.V.. (3/2/20). "Press Release: Uniqure Announces 2019 Financial Results and Highlights Recent Company Progress". Lexington, MA & Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.